Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918249 | 0.84 | SLC2A1 (0.41) | MAP1LC3BHTR3AHSD17B10ALDH1A1POLB | |
| SCHEMBL8881329 | 0.81 | KDM1A (0.38) | HSD17B10KMT2AHTR2CHTR2B | |
| SCHEMBL11664924 | 0.81 | GAA (0.39) | MAP1LC3BHSD17B10SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL8880473 | 0.77 | HRH3 (0.39) | FFAR4 | |
| SCHEMBL28329005 | 0.74 | ADRB2 (0.44) | ADRB2MAP1LC3BHTR3AHSD17B10ALDH1A1 | |
| SCHEMBL12020608 | 0.73 | HTR3A (0.47) | ADRB2MAP1LC3BHTR3AHSD17B10ALDH1A1 | |
| Formic Acid SCHEMBL28032561 | 0.72 | MAP1LC3B (0.35) | ADRB2MAP1LC3BHSD17B10ALDH1A1POLB | |
| SCHEMBL23525773 | 0.67 | HTR3A (0.45) | ADRB2MAP1LC3BHTR3AHSD17B10ALDH1A1 | |
| SCHEMBL12020436 | 0.67 | HTR3A (0.45) | ADRB2MAP1LC3BHTR3AHSD17B10ALDH1A1 | |
| SCHEMBL29992139 | 0.67 | HTR3A (0.45) | ADRB2HTR3AHSD17B10ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2816040-B1 | Process for the production of CCR2 receptor antagonists and intermediates thereof | CENTREXION THERAPEUTICS CORP (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
| CN-103724328-B | Cyclic pyrimidin-4-the methane amide of inflammation, asthma and COPD is used for the treatment of as CCR2 receptor antagonist | BOEHRINGER INGELHEIM INT (DE) | 2015-10-14 | — | — | CN | disclosed |
| EP-2379525-B1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INT (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| EP-2816040-A1 | Process for the production of CCR2 receptor antagonists and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-24 | — | — | EP | disclosed |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8835440-B2 | Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| CN-102256963-B | Cyclic pyrimidine-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD | BOEHRINGER INGELHEIM INT | 2014-06-11 | — | — | CN | disclosed |
| CN-103724328-A | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd | BOEHRINGER INGELHEIM INT | 2014-04-16 | — | — | CN | disclosed |
| US-20130324517-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-05 | — | — | US | disclosed |
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
| EP-2379525-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | Boehringer Ingelheim International GmbH (DE) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010070032-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | CCR2, CCR1, CCR5 | ADRB2 63/4885MAP1LC3B 3632/4885HTR3A 909/4885 |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | CCR2, CCR5, CCR1 | ADRB2 122/4885MAP1LC3B 3750/4885HTR3A 458/4885 |
| US-20130324517-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | CCR2, CCR5, CCR1 | ADRB2 100/4885MAP1LC3B 2883/4885HTR3A 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.